nach oben

Current Cardiology Reports

Erschienen in:

23.11.2020 | COVID-19 | Invasive Electrophysiology and Pacing (E Kevin Heist, Section Editor) Zur Zeit gratis

Home Monitoring of Cardiac Devices in the Era of COVID-19

Erschienen in: Current Cardiology Reports | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Despite the promise of remote patient monitoring (RPM), this technology remained underutilized secondary to a lack of data transparency and systems issues until the COVID-19 pandemic ushered in a new era of telehealth and virtual solutions out of necessity. This review will explore the data supporting the use of RPM via both implantable and wearable devices in the field of cardiology and the role of home monitoring using RPM in the era of COVID-19.

Recent Findings

RPM using implantable cardiac devices is a safe alternative to in-person only visits which leads to enhanced patient satisfaction and improved clinical outcomes. Consumer-grade wearable sensors have drastically expanded RPM capabilities from just the sickest cardiac patients to the entire population aiding in early diagnosis and real-time disease management.

Summary

Home monitoring enabled by automated alert systems tailored specifically to the needs of the patient by the provider will be the cornerstone of a more continuous, patent-centric healthcare model.

Beck H, Boden WE, Patibandla S, Kireyev D, Gupta V, Campagna F, et al. 50th anniversary of the first successful permanent pacemaker implantation in the United States: historical review and future directions. Am J Cardiol. 2010;106:810–8.PubMedCrossRef

Saxon LA, Hayes DL, Gilliam FR, Heidenreich PA, Day J, Seth M, et al. Long-term outcome after ICD and CRT implantation and influence of remote device follow-up: the ALTITUDE survival study. Circulation. 2010;122:2359–67.PubMedCrossRef

Akar JG, Bao H, Jones PW, Wang Y, Varosy PD, Masoudi FA, et al. Use of remote monitoring is associated with lower risk of adverse outcomes among patients with implanted cardiac defibrillators. Circ Arrhythmia Electrophysiol. 2015;8:1173–80.CrossRef

Varma N, Piccini JP, Snell J, Fischer A, Dalal N, Mittal S. The relationship between level of adherence to automatic wireless remote monitoring and survival in pacemaker and defibrillator patients. J Am Coll Cardiol. 2015;65:2601–10.PubMedCrossRef

Slotwiner D, Varma N, Akar JG, Annas G, Beardsall M, Fogel RI, et al. HRS expert consensus statement on remote interrogation and monitoring for cardiovascular implantable electronic devices. Hear Rhythm. 2015;12:e69–e100.CrossRef

•• Miller J, Bose R, Saxon LA. Chapter 63: Personal cardiac monitoring. In: Jalife J, Stevenson W, editors. Zipes & Jalife cardiac electrophysiology: from cell to bedside, 8th edition. Elsevier Health Sciences; 2020. [In Print]

Centers for Medicare & Medicaid Services. CMS payment policies & regulatory flexibilities during COVID-19 emergency. American Medical Association; 2020. https://www.ama-assn.org/practice-management/medicare/cms-payment-policies-regulatory-flexibilities-during-covid-19. Accessed 15 Aug 2020.

Lakkireddy DR, Chung MK, Gopinathannair R, Patton KK, Gluckman TJ, Turagam M, et al. Guidance for cardiac electrophysiology during the COVID-19 pandemic from the heart rhythm society COVID-19 task force; Electrophysiology section of the American College of Cardiology; and the Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology, American Heart Association. Circulation. 2020;141(21):e823–31.

• Abraham WT, Fiuzat M, Psotka MA, O’Connor CM. Heart failure collaboratory statement on heart failure remote monitoring in the landscape of COVID-19 and social distancing. JACC Hear Fail. 2020;8:692. This document provides recommendations pertaining to heart failure management and remote monitoring for patients during the COVD-19 pandemic.CrossRef

10.

Huynh K. Reduced hospital admissions for ACS — more collateral damage from COVID-19. Nat Rev Cardiol. 2020;17:453.PubMedCrossRefPubMedCentral

11.

Yancy CW, Fonarow GC. Coronavirus disease 2019 (COVID-19) and the heart - is heart failure the next chapter? JAMA Cardiol. 2020. https://doi.org/10.1001/jamacardio.2020.3575.

12.

Yee R, Verma A, Beardsall M, Fraser J, Philippon F, Exner DV. Canadian Cardiovascular Society/Canadian Heart Rhythm Society joint position statement on the use of remote monitoring for cardiovascular implantable electronic device follow-up. Can J Cardiol. 2013;29:644–51.PubMedCrossRef

13.

•• Steinberg JS, Varma N, Cygankiewicz I, et al. 2017 ISHNE-HRS expert consensus statement on ambulatory ECG and external cardiac monitoring/telemetry. Ann Noninvasive Electrocardiol. 2017. https://doi.org/10.1111/anec.12447. This document developed by experts from the International Society for Holter and Noninvasive Electrocardiology and Heart Rhythm Society summarizes the background, provides the framework, and details the guidelines for how best to utilize amblatory electrocardiography techniques in clinical care.

14.

Wilkoff BL, Auricchio A, Brugada J, Cowie M, Ellenbogen KA, Gillis AM, et al. HRS/EHRA expert consensus on the monitoring of cardiovascular implantable electronic devices (CIEDs): description of techniques, indications, personnel, frequency and ethical considerations. Europace. 2008;10:707–25.PubMedCrossRef

15.

Versteeg H, Timmermans I, Widdershoven J, Kimman GJ, Prevot S, Rauwolf T, et al. Effect of remote monitoring on patient-reported outcomes in European heart failure patients with an implantable cardioverter-defibrillator: primary results of the REMOTE-CIED randomized trial. Europace. 2019;21:1360–8.PubMedCrossRef

16.

Hindricks G, Taborsky M, Glikson M, Heinrich U, Schumacher B, Katz A, et al. Implant-based multiparameter telemonitoring of patients with heart failure (IN-TIME): a randomised controlled trial. Lancet. 2014;384:583–90.CrossRefPubMed

17.

Petersen HH, Larsen MCJ, Nielsen OW, Kensing F, Svendsen JH. Patient satisfaction and suggestions for improvement of remote ICD monitoring. J Interv Card Electrophysiol. 2012;34:317–24.PubMedCrossRef

18.

Mabo P, Victor F, Bazin P, Ahres S, Babuty D, Da Costa A, et al. A randomized trial of long-term remote monitoring of pacemaker recipients (the COMPAS trial). Eur Heart J. 2012;33:1105–11.PubMedCrossRef

19.

Crossley GH, Chen J, Choucair W, Cohen TJ, Gohn DC, Johnson WB, et al. Clinical benefits of remote versus transtelephonic monitoring of implanted pacemakers. J Am Coll Cardiol. 2009;54:2012–9.PubMedCrossRef

20.

Crossley GH, Boyle A, Vitense H, Chang Y, Mead RH. The CONNECT (clinical evaluation of remote notification to reduce time to clinical decision) trial: the value of wireless remote monitoring with automatic clinician alerts. J Am Coll Cardiol. 2011;57:1181–9.PubMedCrossRef

21.

Varma N, Epstein AE, Irimpen A, Schweikert R, Love C. Efficacy and safety of automatic remote monitoring for implantable cardioverter-defibrillator follow-up: the lumos-t safely reduces routine office device follow-up (TRUST) trial. Circulation. 2010;122:325–32.PubMedCrossRef

22.

Powell BD, Saxon LA, Boehmer JP, Day JD, Gilliam FR, Heidenreich PA, et al. Survival after shock therapy in implantable cardioverter-defibrillator and cardiac resynchronization therapy-defibrillator recipients according to rhythm shocked: the altitude survival by rhythm study. J Am Coll Cardiol. 2013;62:1674–9.PubMedCrossRef

23.

Hayes DL, Boehmer JP, Day JD, Gilliam F III, Heidenreich PA, Seth M, et al. Cardiac resynchronization therapy and the relationship of percent biventricular pacing to symptoms and survival. Hear Rhythm. 2011;8:1469–75.CrossRef

24.

Morgan JM, Kitt S, Gill J, McComb JM, Ng GA, Raftery J, et al. Remotemanagement of heart failure using implantable electronic devices. Eur Heart J. 2017;38:2352–60.PubMedPubMedCentralCrossRef

25.

Kurek A, Tajstra M, Gadula-Gacek E, et al. Impact of remote monitoring on long-term prognosis in heart failure patients in a real-world cohort: results from all-comers COMMIT-HF trial. J Cardiovasc Electrophysiol. 2017;28:425–31.PubMedCrossRef

26.

Parthiban N, Esterman A, Mahajan R, Twomey DJ, Pathak RK, Lau DH, et al. Remote monitoring of implantable cardioverter-defibrillators: a systematic review and meta-analysis of clinical outcomes. J Am Coll Cardiol. 2015;65:2591–600.PubMedCrossRef

27.

Glotzer TV, Daoud EG, Wyse DG, Singer DE, Ezekowitz MD, Hilker C, et al. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk the trends study. Circ Arrhythmia Electrophysiol. 2009;2:474–80.CrossRef

28.

Healey JS, Connolly SJ, Gold MR, Israel CW, van Gelder I, Capucci A, et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med. 2012;366:120–9.PubMedCrossRef

29.

Pietro RR, Vaccari D, Morichelli L, et al. Stroke incidence in patients with cardiac implantable electronic devices remotely controlled with automatic alerts of atrial fibrillation. A sub-analysis of the HomeGuide study. Int J Cardiol. 2016;219:251–6.CrossRef

30.

Martin DT, Bersohn MM, Waldo AL, Wathen MS, Choucair WK, Lip GYH, et al. Randomized trial of atrial arrhythmia monitoring to guide anticoagulation in patients with implanted defibrillator and cardiac resynchronization devices. Eur Heart J. 2015;36:1660–8.PubMedCrossRef

31.

Raj LM, Saxon LA. Haemodynamic monitoring devices in heart failure: maximising benefit with digitally enabled patient centric care. Arrhythmia Electrophysiol Rev. 2018;7:294–8.CrossRef

32.

FDA. Premarket Approval (PMA). 2014. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P100045. Accessed 10 Mar 2020.

33.

Adamson PB, Abraham WT, Bourge RC, Costanzo MR, Hasan A, Yadav C, et al. Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. Circ Hear Fail. 2014;7:935–44.CrossRef

34.

Abraham WT, Adamson PB, Bourge RC, Aaron MF, Costanzo MR, Stevenson LW, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet. 2011;377:658–66.PubMedCrossRef

35.

Abraham WT, Stevenson LW, Bourge RC, Lindenfeld JA, Bauman JG, Adamson PB. Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial. Lancet. 2016;387:453–61.PubMedCrossRef

36.

• Adamson PB, Ginn G, Anker SD, Bourge RC, Abraham WT. Remote haemodynamic-guided care for patients with chronic heart failure: a meta-analysis of completed trials. Eur J Heart Fail. 2017;19:426–33. This meta-analysis evaluates data from completed clinical trials evaluating the role of remote hemodynamic monitoring in patients with heart failure and concludes the superior treatment of “permanently implanted sensors and frequent filling pressure evaluation” in reducing the risk of long-term hospitalization for heart failure in comparison to traditional clinical management.PubMedCrossRef

37.

Desai AS, Bhimaraj A, Bharmi R, Jermyn R, Bhatt K, Shavelle D, et al. Ambulatory hemodynamic monitoring reduces heart failure hospitalizations in “real-world” clinical practice. J Am Coll Cardiol. 2017;69:2357–65.PubMedCrossRef

38.

Raval NY, Shavelle D, Bourge RC, Costanzo MR, Shlofmitz R, Heywood JT, et al. Significant reductions in heart failure hospitalizations with the pulmonary artery pressure guided HF system: preliminary observations from the CardioMEMS post approval study. J Card Fail. 2017;23:S27.CrossRef

39.

• Shavelle DM, Desai AS, Abraham WT, et al. Lower rates of heart failure and all-cause hospitalizations during pulmonary artery pressure-guided therapy for ambulatory heart failure. Circ Hear Fail. 2020. https://doi.org/10.1161/circheartfailure.119.006863. This multi-center, prospective study is the largest of its kind to evaluate the outcomes of ambulatory hemodynamics moitoring of patients with implantable pulmonary artery sensors.

40.

Sanna T, Diener H-C, Passman RS, di Lazzaro V, Bernstein RA, Morillo CA, et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med. 2014;370:2478–86.CrossRefPubMed

41.

Steinhubl SR, Waalen J, Edwards AM, Ariniello LM, Mehta RR, Ebner GS, et al. Effect of a home-based wearable continuous ECG monitoring patch on detection of undiagnosed atrial fibrillation the mSToPS randomized clinical trial. JAMA - J Am Med Assoc. 2018;320:146–55.CrossRef

42.

Steinhubl SR, Mehta RR, Ebner GS, Ballesteros MM, Waalen J, Steinberg G, et al. Rationale and design of a home-based trial using wearable sensors to detect asymptomatic atrial fibrillation in a targeted population: the mHealth screening to prevent strokes (mSToPS) trial. American Heart Journal. 2016;175:77–85.

43.

Halcox JPJ, Wareham K, Cardew A, Gilmore M, Barry JP, Phillips C, et al. Assessment of remote heart rhythm sampling using the AliveCor heart monitor to screen for atrial fibrillation the REHEARSE-AF study. Circulation. 2017;136:1784–94.PubMedCrossRef

44.

Lau JK, Lowres N, Neubeck L, Brieger DB, Sy RW, Galloway CD, et al. IPhone ECG application for community screening to detect silent atrial fibrillation: a novel technology to prevent stroke. Int J Cardiol. 2013;165:193–4.PubMedCrossRef

45.

Lowres N, Neubeck L, Salkeld G, Krass I, McLachlan AJ, Redfern J, et al. Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies: the SEARCH-AF study. Thromb Haemost. 2014;111:1167–76.PubMedCrossRef

46.

Chan PH, Wong CK, Pun L, Wong YF, Wong MMY, Chu DWS, et al. Head-to-head comparison of the AliveCor heart monitor and microlife WatchBP office AFIB for atrial fibrillation screening in a primary care setting. Circulation. 2017;135:110–2.PubMedCrossRef

47.

Bumgarner JM, Lambert CT, Hussein AA, Cantillon DJ, Baranowski B, Wolski K, et al. Smartwatch algorithm for automated detection of atrial fibrillation. J Am Coll Cardiol. 2018;71:2381–8.PubMedCrossRef

48.

Statement from FDA commissioner Scott Gottlieb, M.D., and center for devices and radiological health director Jeff Shuren, M.D., J.D., on agency efforts to work with tech industry to spur innovation in digital health | FDA. https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-and-center-devices-and-radiological-health-director. Accessed 20 Aug 2020.

49.

• Perez MV, Mahaffey KW, Hedlin H, et al. Large-scale assessment of a smartwatch to identify atrial fibrillation. N Engl J Med. 2019;381:1909–17. This peer-reviewed publication shares the results of the Apple Heart Study demonstrating that the Apple Watch AF algorithm can successfully detect and the feasibility of completing a siteless study based on data from consumer owned devices.PubMedCrossRefPubMedCentral

50.

ECG app and irregular heart rhythm notification available today on Apple Watch - Apple. https://www.apple.com/newsroom/2018/12/ecg-app-and-irregular-heart-rhythm-notification-available-today-on-apple-watch/. Accessed 26 Feb 2020.

51.

Iqbal S Apple ResearchKit, HealthKit and CareKit, Health App – what does it all mean? https://www.biotaware.com/blog/apple-researchkit-healthkit-and-carekit-health-app-what-does-it-all-mean/. Accessed 26 Feb 2020.

52.

(2020) About the Heartline Study by Johnson & Johnson and Apple. https://www.heartline.com/about. Accessed 28 Aug 2020.

53.

Telehealth: A post-COVID-19 reality? | McKinsey. https://www.mckinsey.com/industries/healthcare-systems-and-services/our-insights/telehealth-a-quarter-trillion-dollar-post-covid-19-reality#. Accessed 24 Aug 2020.

54.

Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5:802–10.PubMedPubMedCentralCrossRef

55.

Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5:1.PubMedCentralCrossRef

56.

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA - J Am Med Assoc. 2020;323:1061–9.CrossRef

57.

Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen R, Jabri A, et al. Clinical characteristics of Covid-19 in New York City. N Engl J Med. 2020;382:2372–4.PubMedCrossRef

58.

Bhatla A, Mayer MM, Adusumalli S, Hyman MC, Oh E, Tierney A, et al. COVID-19 and cardiac arrhythmias. Hear Rhythm. 2020;17:1439–44. https://doi.org/10.1016/j.hrthm.2020.06.016.CrossRef

59.

Dherange P, Lang J, Qian P, Oberfeld B, Sauer WH, Koplan B, et al. Arrhythmias and COVID-19: a review. JACC Clin Electrophysiol. 2020;6:1193–204. https://doi.org/10.1016/j.jacep.2020.08.002.CrossRefPubMedPubMedCentral

60.

Hu H, Ma F, Wei X, Fang Y. Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin. Eur Heart J. 2020. https://doi.org/10.1093/eurheartj/ehaa190.

61.

Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Biondi-Zoccai G, et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. J Am Coll Cardiol. 2020;75:2352–71.PubMedPubMedCentralCrossRef

62.

• Puntmann VO, Carerj ML, Wieters I, et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020. https://doi.org/10.1001/jamacardio.2020.3557. This publication shared cohort study results showing the increased risk of lasting cardiac effects in recently recovering from COVID-19 infection as evidenced by signs of ongoing cardiac inflammation in patients seen on MRI.

63.

Minguito-Carazo C, Echarte-Morales J, Benito-González T, et al. QT interval monitoring with handheld heart rhythm ECG device in COVID-19 patients. 2020. https://doi.org/10.21203/rs.3.rs-38108/v1.

64.

Giudicessi JR, Noseworthy PA, Friedman PA, Ackerman MJ. Urgent guidance for navigating and circumventing the QTc-prolonging and torsadogenic potential of possible pharmacotherapies for coronavirus disease 19 (COVID-19). Mayo Clin Proc. 2020;95:1213–21.PubMedCrossRef

65.

Mercuro NJ, Yen CF, Shim DJ, Maher TR, McCoy CM, Zimetbaum PJ, et al. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5:1036–41. https://doi.org/10.1001/jamacardio.2020.1834.CrossRefPubMed

66.

Remote or wearable patient monitoring devices EUAs | FDA. https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/remote-or-wearable-patient-monitoring-devices-euas?utm_campaign=2020-06-18NewEUACOVID-19page&utm_medium=email&utm_source=Eloqua. Accessed 15 Aug 2020.

67.

COVID-19 in-home monitoring program launched – Washington University School of Medicine in St. Louis. https://medicine.wustl.edu/news/covid-19-in-home-monitoring-program-launched/. Accessed 21 Jul 2020.

68.

Medina M, Babiuch C, Card M, Gavrilescu R, Zafirau W, Boose E, et al. Home monitoring for COVID-19: posted April 18, 2020. Cleve Clin J Med. 2020;87:1–4.

69.

Mayo clinic teams with medically home to expand in-home hospital care | FierceHealthcare. https://www.fiercehealthcare.com/hospitals/mayo-clinic-teams-medically-home-to-expand-home-hospital-car. Accessed 24 Aug 2020.

70.

Apple Watch users can monitor their body’s response to COVID-19, flu with Cardiogram app | Appleinsider. https://appleinsider.com/articles/20/03/19/apple-watch-users-can-monitor-their-bodys-response-to-covid-19-flu-with-cardiogram-app. Accessed 22 Jul 2020.

71.

• Radin JM, Wineinger NE, Topol EJ, Steinhubl SR. Harnessing wearable device data to improve state-level real-time surveillance of influenza-like illness in the USA: a population-based study. Lancet Digit Heal. 2020;2:e85–93. This publication highlights the possibility of monitoring viral outbreaks across wide populations through the use of digital surveillance tools, such as activity trackers and other wearable and mobile devices.CrossRef

72.

Natarajan A, Su H-W, Heneghan C. Assessment of physiological signs associated with COVID-19 measured using wearable devices. https://doi.org/10.1101/2020.08.14.20175265.

73.

Heart Rate & Valuable WHOOP Data in COVID-19 | Coronavirus | WHOOP. https://www.whoop.com/thelocker/whoop-data-coronavirus/. Accessed 21 Jul 2020.

74.

Oura partners with the NBA to help players, coaches, and staff understand their health as the season resumes. https://ouraring.com/partners-with-the-nba. Accessed 24 Aug 2020.

75.

Masimo and university hospitals jointly announce Masimo SafetyNet™, a new remote patient monitoring solution | University Hospitals Newsroom. https://news.uhhospitals.org/news-releases/masimo-and-university-hospitals-jointly-announce-masimo-safetynet-a-new-remote-patient-monitoring-solution.htm. Accessed 24 Aug 2020.

Titel: Home Monitoring of Cardiac Devices in the Era of COVID-19
Publikationsdatum: 23.11.2020
Schlagwort: COVID-19
Erschienen in: Current Cardiology Reports / Ausgabe 1/2021
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI: https://doi.org/10.1007/s11886-020-01431-w

Neu im Fachgebiet Kardiologie

25.04.2024 | Hypertonie | Nachrichten

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Home Monitoring of Cardiac Devices in the Era of COVID-19

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet Kardiologie

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Myokarditis nach Infekt – Richtig schwierig wird es bei Profisportlern

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Update Kardiologie

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2021

Cardiac Sympathetic Innervation Imaging with PET Radiotracers

Multimodality Imaging of Myocardial Viability

Management of Arrhythmias Associated with COVID-19

The Role of Autoantibodies in Arrhythmogenesis

Neu im Fachgebiet Kardiologie

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Myokarditis nach Infekt – Richtig schwierig wird es bei Profisportlern

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Update Kardiologie